JP2010513440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513440A5 JP2010513440A5 JP2009542202A JP2009542202A JP2010513440A5 JP 2010513440 A5 JP2010513440 A5 JP 2010513440A5 JP 2009542202 A JP2009542202 A JP 2009542202A JP 2009542202 A JP2009542202 A JP 2009542202A JP 2010513440 A5 JP2010513440 A5 JP 2010513440A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- rhinitis
- laba
- induced
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 description 8
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 4
- 229940125389 long-acting beta agonist Drugs 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229960004017 salmeterol Drugs 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- 229940110309 tiotropium Drugs 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87092206P | 2006-12-20 | 2006-12-20 | |
| US91004507P | 2007-04-04 | 2007-04-04 | |
| US95198007P | 2007-07-26 | 2007-07-26 | |
| PCT/GB2007/004861 WO2008075026A1 (en) | 2006-12-20 | 2007-12-19 | 4-hydr0xy-2-0x0-2, 3 -dihydro- 1, 3-benzothiazol- 7yl compounds for modulation of b2-adrenoreceptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513440A JP2010513440A (ja) | 2010-04-30 |
| JP2010513440A5 true JP2010513440A5 (https=) | 2011-02-10 |
Family
ID=39167020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542202A Pending JP2010513440A (ja) | 2006-12-20 | 2007-12-19 | Ｂ２アドレナリン受容体活性の調節用４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−イル化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20100022491A1 (https=) |
| EP (1) | EP2121642B1 (https=) |
| JP (1) | JP2010513440A (https=) |
| KR (1) | KR20090091342A (https=) |
| AR (1) | AR064635A1 (https=) |
| AT (1) | ATE517879T1 (https=) |
| AU (1) | AU2007336075B2 (https=) |
| BR (1) | BRPI0722096A2 (https=) |
| CA (1) | CA2672811A1 (https=) |
| CL (1) | CL2007003765A1 (https=) |
| CO (1) | CO6190554A2 (https=) |
| EC (1) | ECSP099426A (https=) |
| IL (1) | IL199014A0 (https=) |
| MX (1) | MX2009006009A (https=) |
| NO (1) | NO20092691L (https=) |
| PE (1) | PE20081544A1 (https=) |
| SA (1) | SA07280728B1 (https=) |
| TW (1) | TW200833670A (https=) |
| UY (1) | UY30808A1 (https=) |
| WO (1) | WO2008075026A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| EA017627B1 (ru) | 2008-05-13 | 2013-01-30 | Астразенека Аб | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора |
| CN102088976B (zh) * | 2008-05-13 | 2012-12-26 | 阿斯利康(瑞典)有限公司 | 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 |
| WO2009154557A1 (en) | 2008-06-18 | 2009-12-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
| AU2009260904A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
| GB0814728D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| WO2015050984A1 (en) * | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2653977A (en) * | 1953-09-29 | Chxnx | ||
| US3775477A (en) * | 1971-03-10 | 1973-11-27 | Sterling Drug Inc | N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides |
| US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| EP0162576B1 (en) | 1984-04-17 | 1989-07-26 | Glaxo Group Limited | Ethanolamine compounds |
| US4554284A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| US4554287A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
| GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
| GB8718938D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
| NZ235605A (en) | 1989-10-10 | 1992-12-23 | Glaxo Group Ltd | (r)-(-)-4-hydroxy-alpha 1 -(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol and pharmaceutical compositions |
| US5648370A (en) * | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
| GB9211172D0 (en) | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
| GB9210632D0 (en) | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| IE914003A1 (en) * | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| TW356468B (en) | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
| GB9526511D0 (en) | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
| DE69709647T2 (de) | 1996-05-20 | 2002-11-07 | Dupont Pharmaceuticals Research Laboratories, Inc. | Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren |
| SE9700706D0 (sv) | 1997-02-27 | 1997-02-27 | Astra Pharma Prod | Process for the preparation of benzothiazoline compounds |
| SE9701304D0 (sv) | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
| JP2002509119A (ja) | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物 |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902937D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902936D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| SE9902938D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| CA2565243A1 (en) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| BRPI0511695A (pt) | 2004-06-03 | 2008-01-08 | Theravance Inc | agonistas de receptor (beta)2 adrenérgico diamina |
| WO2006014704A1 (en) | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP1786762A2 (en) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| AU2006205933A1 (en) | 2005-01-11 | 2006-07-20 | Glaxo Group Limited | Cinnamate salts of a beta-2 adrenergic agonist |
| GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| NZ585580A (en) | 2005-07-18 | 2011-08-26 | Pfizer Ltd | Process for the preparation of sulfonamide derivatives |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| US20090029958A1 (en) * | 2006-03-08 | 2009-01-29 | Lilian Alcaraz | Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2008041914A1 (en) | 2006-10-06 | 2008-04-10 | Astrazeneca Ab | 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| CA2672792A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
| GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
| GB0702458D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0704000D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| MX2010006657A (es) * | 2007-12-20 | 2010-10-05 | Astrazeneca Ab | Dispositivo y metodo para desagregar polvo 854. |
| AU2009260904A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
-
2007
- 2007-12-07 TW TW096146813A patent/TW200833670A/zh unknown
- 2007-12-19 CA CA002672811A patent/CA2672811A1/en not_active Abandoned
- 2007-12-19 US US12/519,552 patent/US20100022491A1/en not_active Abandoned
- 2007-12-19 JP JP2009542202A patent/JP2010513440A/ja active Pending
- 2007-12-19 US US11/959,679 patent/US7700782B2/en not_active Expired - Fee Related
- 2007-12-19 EP EP07848598A patent/EP2121642B1/en active Active
- 2007-12-19 BR BRPI0722096-0A2A patent/BRPI0722096A2/pt not_active IP Right Cessation
- 2007-12-19 AT AT07848598T patent/ATE517879T1/de not_active IP Right Cessation
- 2007-12-19 MX MX2009006009A patent/MX2009006009A/es active IP Right Grant
- 2007-12-19 WO PCT/GB2007/004861 patent/WO2008075026A1/en not_active Ceased
- 2007-12-19 UY UY30808A patent/UY30808A1/es unknown
- 2007-12-19 AU AU2007336075A patent/AU2007336075B2/en not_active Ceased
- 2007-12-19 KR KR1020097015062A patent/KR20090091342A/ko not_active Withdrawn
- 2007-12-20 CL CL200703765A patent/CL2007003765A1/es unknown
- 2007-12-20 AR ARP070105801A patent/AR064635A1/es not_active Application Discontinuation
- 2007-12-29 SA SA7280728A patent/SA07280728B1/ar unknown
-
2008
- 2008-01-02 PE PE2008000009A patent/PE20081544A1/es not_active Application Discontinuation
-
2009
- 2009-05-27 CO CO09054440A patent/CO6190554A2/es not_active Application Discontinuation
- 2009-05-27 IL IL199014A patent/IL199014A0/en unknown
- 2009-06-15 EC EC2009009426A patent/ECSP099426A/es unknown
- 2009-07-15 NO NO20092691A patent/NO20092691L/no not_active Application Discontinuation
-
2010
- 2010-03-30 US US12/750,014 patent/US20100249200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513440A5 (https=) | ||
| HRP20201147T1 (hr) | (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i | |
| ES3028423T3 (en) | Norketotifen for use in the treatment of respiratory disorders | |
| US20100092397A1 (en) | Method For Treatment of COPD and Other Pulmonary Diseases | |
| JP2016510804A5 (https=) | ||
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| MX2011010209A (es) | Composicion farmaceutica que comprende un derivado de pirazol esteroidal[3,2-c] y un segundo compuesto activo farmaceutico. | |
| AU2010258751A1 (en) | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration | |
| JP2013531056A5 (https=) | ||
| TWI905086B (zh) | 包含雷芬那新（ｒｅｖｅｆｅｎａｃｉｎ）之醫藥組合物用於治療慢性阻塞性肺疾病之用途及選擇治療用之吸入遞送裝置之方法 | |
| CA2575932A1 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| CN101883562A (zh) | 包含西替利嗪以及非β-2-肾上腺素受体激动剂、β-2-肾上腺素受体激动剂或消炎药的组合物及其用于治疗呼吸疾病的用途 | |
| US20080261932A1 (en) | Methods and compositions for the prevention and/or treatment of an exacerbation of asthma | |
| ES2610104T3 (es) | Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias | |
| JP2013538867A (ja) | 新規組合せ剤 | |
| JP2008502699A5 (https=) | ||
| WO2023156808A3 (en) | Compositions and methods for treating pulmonary disorders | |
| US20120101076A1 (en) | Carbonate derivatives for the treatment of cough | |
| CN104758294A (zh) | 用于copd、哮喘治疗的吸入药物组合物及其制备方法 | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| Shah | Treatment of Asthma and COPD 32 | |
| Smith | A review of bronchodilators for chronic obstructive pulmonary disease | |
| WO2026052051A1 (zh) | 杂环化合物在治疗肺疾病中的应用 | |
| Chunder | Chronic obstructive pulmonary disease: which bronchodilators? | |
| Al-Hasani | Drugs used to treat chronic obstructive pulmonary disease (COPD) |